RESEARCH MONOGRAPH · KDC-MN-351

Low-Dose Naltrexone (LDN)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

72/100

Real mechanism story under a lot of internet noise, but the human evidence is patchy

LDN is interesting because the mechanism story is more coherent than skeptics give it credit for, but the clinical evidence is much thinner than enthusiasts admit. Both things are true.

The mechanistic case rests on two parallel stories. First, transient mu-opioid blockade at low doses (typically 1 to 4.5 mg) producing a rebound increase in endogenous opioid signaling, particularly enkephalins and met-enkephalin. The Zagon group has been on this for decades and the receptor upregulation hypothesis is the framework most LDN advocates point to. Second, TLR4 antagonism on microglia, where naltrexone (and especially the (+) enantiomer) damps neuroinflammatory signaling independent of opioid receptors. The Hutchinson and Watkins work on this is solid and matters because it explains why LDN might do something in conditions with a strong neuroinflammatory component (fibromyalgia, Crohn's, MS, complex regional pain syndrome).

The human evidence is the problem. The fibromyalgia trials (Younger and Mackey at Stanford) are small but the effect size on pain is real and the crossover design makes it hard to dismiss. The Crohn's data (Smith group) is similarly small but consistent. MS, autoimmune thyroid, complex regional pain, theres signal but its almost all single-site small trials or open-label observational work, and large randomized replication is mostly missing.

What we like is that the mechanism is biologically grounded in a way that LDN's internet presence often obscures. This isn't a nothing-burger.

What we dont like is how the LDN community treats it as a panacea for every chronic condition. The evidence does not support that, and the conflation of glial TLR4 effects with general anti-inflammatory action gets a lot of papers cited beyond what they actually say.

Sourcing is straightforward. Naltrexone hydrochloride is a well-characterized small molecule, stable, HPLC validation is routine, and the low-dose research formulations (compounded suspensions, microtab approaches) are standard chemistry. The dose math is where most variability lives.

For research, LDN remains an interesting probe for TLR4-glia interactions and endogenous opioid rebound. We just dont know yet how big the effects are at clinically relevant doses in well-controlled trials.

Evidence: 55
Mechanism: 70
Reliability: 60
Safety: 85
Sourcing: 88
Value: 80
Signal: 70
Staying power: 70

Plain-language summary Intrigue 70 / 100

Low-dose naltrexone (LDN) uses the standard opioid antagonist naltrexone at one-tenth to one-twentieth of the dose approved for opioid and alcohol use disorders. The proposed mechanism involves brief overnight opioid blockade that triggers compensatory upregulation of the body's own endogenous opioid system, plus TLR4 antagonism on microglia that may dampen central inflammation. Bernard Bihari pioneered the protocol in the 1980s. LDN has accumulated a substantial body of small clinical trials and case series in fibromyalgia, multiple sclerosis, Crohn disease, and various autoimmune conditions, with effect sizes that look real but evidence quality that remains modest. It is generally well-tolerated and inexpensive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Mu-opioid antagonist (low-dose immunomodulatory use)

A mu-opioid antagonist used at low doses (1.5 to 4.5 mg) for autoimmune and chronic pain conditions; mechanism via transient opioid blockade and TLR4 modulation.

Abstract

Naltrexone ((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; CAS 16590-41-3; molecular formula C20H23NO4; molecular weight 341.40) is a long-acting mu-opioid antagonist approved by the FDA in 1984 (ReVia, Vivitrol) for opioid and alcohol use disorders at standard doses (50 mg or 380 mg depot). The low-dose application (LDN, 1.5 to 4.5 mg) was developed by Bernard Bihari in the 1980s and has been adopted in immunology and chronic pain communities. Mechanism is multifactorial and incompletely characterized: brief, transient mu-opioid antagonism (only 4 to 6 hours in the published literature) triggers compensatory upregulation of endogenous opioid synthesis and receptor expression, producing a paradoxical increase in opioid-mediated tone over baseline; secondary TLR4 antagonism on microglia attenuates neuroinflammation. Approved indications: opioid and alcohol use disorders (standard dose). Off-label LDN use in multiple sclerosis, Crohn disease, fibromyalgia, complex regional pain syndrome, and Hashimoto thyroiditis is supported by small clinical trials with mixed methodology. Plasma half-life is approximately 4 hours. Used as a research compound for paradoxical opioid pharmacology and neuroimmune modulation.

Mechanism of action

Brief mu-opioid antagonism producing compensatory endogenous opioid upregulation; TLR4 antagonism on microglia. Distinct from standard-dose naltrexone in OUD/AUD.

Reported research dose ranges

Off-label LDN 1.5 to 4.5 mg in the published literature. Standard naltrexone OUD 50 mg.

References

Younger J, et al. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014.
Smith JP, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007.
Bihari B. Low-dose naltrexone for normalizing immune system function. Altern Ther Health Med 2013.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-351

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Low-Dose Naltrexone (LDN)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs